New pain pill AFA-281 takes first step in human safety trial
Knowledge-focused
Completed
This early-stage study tested the safety and tolerability of a new drug called AFA-281 in 64 healthy volunteers. Participants received either a single dose or multiple doses over 14-21 days. The goal was to check for side effects and measure how the drug behaves in the body, not …
Phase: PHASE1 • Sponsor: Afasci Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC